Core Insights - The healthcare industry has shown resilience for investors, particularly with companies like Eli Lilly and Intuitive Surgical presenting strong long-term growth potential [3][8] Company Analysis: Eli Lilly - Eli Lilly has gained significant attention due to its successful GLP-1 franchise, despite facing pressures from potential U.S. government interventions aimed at lowering drug prices and recent pharma tariffs [4] - The company is making substantial investments in manufacturing, with plans for multibillion-dollar expansions in the U.S. to enhance production capacity for its popular medications [5] - Eli Lilly reported a 38% year-over-year revenue increase to $15.6 billion in Q2, alongside a 61% spike in non-GAAP earnings per share [6] - The company is advancing a promising drug pipeline in oncology, immunology, and neuroscience, with recent positive trial results for its oral GLP-1 treatment, orforglipron, which could attract patients who prefer non-injectable options [7] - The GLP-1 boom represents just the latest phase in Eli Lilly's growth story, which has a storied history in the pharmaceutical industry [8]
2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon